Eric Van Cutsem, MD, PhD

Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival

Background The APACT trial evaluated the safety and efficacy of adjuvant nab -P + Gem vs Gem alone in patients with resected PC. Between April 2014 and April 2016, 866 patients were rando...

Eric Van Cutsem , MD, PhD;

06/30/2021

LBA-001: Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: Phase III POLO trial

Access the abstract 

Giampaolo Tortora ;

Talia Golan , MD;

Michael J. Hall ;

Pascal Hammel ;

Eric Van Cutsem , MD, PhD;

Michele Reni ;

Teresa Macarulla , MD, PhD;

Joon Oh Park ;

Daniel Hochhauser ;

Dirk Arnold , MD, PhD;

Do-Youn Oh ;

Anke Reinacher-Schick ;

Hana Algül ;

Eileen M. O'Reilly ;

David McGuinness ;

Karen Y. Cui ;

Katia Schlienger ;

Gershon Y. Locker ;

Hedy L. Kindler ;

07/31/2019

Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup

Background The global Phase 3 study RATIONALE 302 (NCT03430843) evaluated the efficacy and safety of second-line tislelizumab, an anti-PD-1 antibody, in patients with advanced or metastat...

Eric Van Cutsem , MD, PhD;

07/03/2021

Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers

    Membranous expression of AMHRII is present in about 80% of colorectal adenocarcinomas. Murlentamab is a glycoengineered mAb binding with high affinity both AMHRII on the t...

Eric Van Cutsem , MD, PhD;

07/01/2019

Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response

Background Most cholangiocarcinoma (CCA) patients are diagnosed with advanced disease and are ineligible for surgery. First-line, standard-of-care therapy for patients with advanced/metas...

G. Vaccaro ;

D. Melisi ;

R. Al-Rajabi ;

A. Paulson ;

M. Borad ;

D. Gallinson ;

D. Oh ;

E. Dotan ;

Daniel Catenacci , MD;

Eric Van Cutsem , MD, PhD;

A. Murphy ;

C. Lihou ;

H. Ren ;

K. Bibeau ;

Ghassan Abou-Alfa , MD, MBA;

L. Feliz ;

V. Sahai ;

Arndt Vogel , MD;

A. Hollebecque ;

06/28/2021

O-002: Ibrutinib in Combination With Nab-Paclitaxel and Gemcitabine as First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma: Results From the Phase 3 RESOLVE Study

Access the abstract

Jean-Baptiste Bachet ;

Heung-Moon Chang ;

Joan Maurel ;

Lisa M. Coussens ;

Lawrence Fong ;

L. Claire Tsao ;

George Cole Jr.;

Danelle James ;

Michele Reni ;

Do-Youn Oh ;

Eric Van Cutsem , MD, PhD;

Margaret A. Tempero , MD;

Teresa Macarulla , MD, PhD;

Josep Tabernero , MD, PhD;

Andrew Hendifar ;

Naureen Starling , MBBS, MD;

Dirk-Thomas Waldschmidt ;

Sara Lonardi ;

07/31/2019

A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

Background Patients with MSI-H/dMMR mCRC treated with chemotherapy have poorer outcomes than patients with microsatellite stable/MMR proficient mCRC. Pembrolizumab monot...

T. Andre ;

Sara Lonardi ;

S. Abdullaev ;

M. Lei ;

L. Jensen ;

C. De la Fouchardiere ;

E. Elez ;

J. Bennouna ;

G. Mendez ;

J. Li ;

Eric Van Cutsem , MD, PhD;

E. Goekkurt ;

T. Chen ;

Takayuki Yoshino , MD, PhD;

06/27/2022

Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial

Eric Van Cutsem , MD, PhD;

07/01/2019

KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage IV colorectal cancer – preliminary results from a phase 1b study

Background Microsatellite stable/mismatch repair proficient (MSS/MMRp) stage IV colorectal cancer (CRC) remains an area of high unmet medical need, with the vast majority not responding t...

Eric Van Cutsem , MD, PhD;

07/01/2021

Multidisciplinary Tumor Board: A Challenging Patient With Colorectal Cancer

Josep Tabernero , MD, PhD;

Thomas Gruenberger , MD;

Sharlene Gill , MD, MPH, MBA, FRCPC;

Michel P. Ducreux , MD, PhD;

Eric Van Cutsem , MD, PhD;

Axel Grothey , MD;

07/19/2019